cCAM Biotherapeutics
acquired
acquired
Stage
1
Investors
About
cCAM Biotherapeutics develops immunotherapies for cancer, including CM-24, an immunomodulatory antibody that blocks a novel immune checkpoint to enhance the immune system's ability to attack tumors. The company was acquired by Merck in July 2015.
Explore cCAM Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.